Antiva Biosciences CEO Gail Maderis (L) is passing the baton to Kristine Ball

‘Sleep­ing block­buster’: MPM leads $53M Se­ries E for An­ti­va as biotech seeks sec­ond go at tack­ling HPV 

An­ti­va Bio­sciences has picked up an­oth­er $53 mil­lion to bankroll two key stud­ies of its top­i­cal drug for high-risk HPV in­fec­tions and pre-can­cer­ous le­sions.

The decade-old South San Fran­cis­co biotech will test ABI-2280 in a glob­al Phase II clin­i­cal tri­al in high-grade pre­can­cer­ous cer­vi­cal le­sions — known as cer­vi­cal in­traep­ithe­lial neo­pla­sia (CIN 2,3) — and run an ex­plorato­ry study to see if it can be a treat­ment for high-risk HPV in­fec­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.